ARCE Therapeutics, a subsidiary of Compal, recently announced that its investigational drug ARD103 CAR-T has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Chien-tsun Kuan, CEO and General Manager of ARCE Therapeutics, emphasized that receiving the ODD designation confers numerous benefits, including priority review, tax credits for clinical trial expenses, waivers for Prescription Drug User Fees, and seven years of market exclusivity in the U.S. following approval.
ARD103 is an autologous CAR-T cell therapy developed using ARCE’s DashCAR rapid manufacturing platform. It specifically targets the CLL-1 (C-type lectin-like molecule-1) antigen found on AML cells, offering a promising treatment for patients with relapsed/refractory AML (r/r AML), a population currently lacking effective therapies.
ARD103 incorporates a next-generation CAR genetic structure that has been optimized for performance. Leveraging DashCAR technology, ARD103 can be manufactured in just 3-5 days, compared to the typical 2-4 weeks required by existing CAR-T therapies. The process preserves the stemness of CAR-T cells, enhancing their growth and persistence in the body, which are critical for effective cell-based treatments.
The rapid production capability of DashCAR addresses the urgent clinical needs of r/r AML patients, for whom time is a critical factor due to the aggressive nature of the disease. This breakthrough dramatically reduces waiting periods for CAR-T therapy, offering hope to patients who previously faced delays in receiving life-saving treatment.
Acute myeloid leukemia (AML) is a rare and aggressive cancer characterized by the excessive proliferation of myeloid cells, which disrupt normal blood cell production. Without treatment, AML progresses rapidly, often leading to death within weeks or months.
Current standard chemotherapy achieves complete remission in approximately 60% of AML patients, but the presence of leukemic stem cells (LSCs) often results in relapse for 40-80% of patients, with subsequent treatments proving ineffective. While small-molecule targeted therapies exist for r/r AML, their application is limited to patients with specific genetic mutations, representing less than 30% of the population.
In October, ARD103 received FDA Investigational New Drug (IND) approval to initiate Phase I/II clinical trials for r/r AML. Combined with the recent ODD designation, this marks another critical step forward in addressing the unmet needs of AML patients.
Chien-tsun Kuan expressed his excitement about the progress of ARD103, highlighting the company’s commitment to accelerating clinical trials to bring safe and effective cell therapies to patients as soon as possible. With this groundbreaking therapy, ARCE Therapeutics aims to make a significant impact on the lives of patients suffering from rare diseases like AML.
Resource: 承寶生技急性骨髓性白血病新藥獲美孤兒藥認定，未來上巿可享7年獨賣
